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Infection with HIV-2 has important implications for the diagnosis, treatment and 
management of the infection.  The objective of this study was to describe the seroprevalence 
and molecular epidemiology of HIV-2 in KwaZulu-Natal – the province with the highest HIV 
prevalence in South Africa, which in turn is the country with the highest HIV prevalence in 
the world.  HIV-1 positive samples were screened using a rapid test for HIV-2.  Samples 
showing antibody positivity were subject to molecular confirmation by PCR and / or 
serological confirmation by Western blot.  There was a large difference in results (10.6% by 
Western blotting versus 0% by PCR).  This discrepancy between molecular and serological 
confirmation was attributed to cross-reacting antibodies.  The use of rapid tests and Western 
blots for HIV-2 diagnosis in South Africa, should, therefore, be interpreted with caution.  
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The etiological agent of acquired immunodeficiency syndrome (AIDS) is designated human 
immunodeficiency virus (HIV).  This virus is a member of the genus lentivirus and belongs to 
the Retroviridae family. HIV is highly mutable, producing many different strains. 
Classification of HIV is based on genetic similarities, and can thus be divided into different 
types, groups and subtypes.  Accordingly, HIV can be separated into types 1 and 2 (Quinn, 
1994).  HIV-2 can further be divided into seven subtypes (A to G).  Subtypes A and B are 
categorized as epidemic subtypes, while C – G are non-epidemic subtypes.  Subtype A is the 
most predominant and is proposed as the most pathogenic.  An intersubtype recombinant 
involving subtypes A and B has been recently described in Cameroon. (Soriano et al., 2000, 
Lemey et al., 2003, Ntemgwa et al., 2009).  A highly divergent HIV-2 strain was identified in 
2004 and Damond et al proposed classification of this strain into a new subtype H (Damond 




1.2 Discovery and Origin of HIV-2 
 
In 1986, three years following the discovery of HIV-1, another related immune-deficiency-
causing virus was isolated. Sera from a cohort of Senegalese sex workers were found to react 
preferentially with antigens from simian immunodeficiency virus (SIV) - a related lentivirus.  
Phylogenenetic analyses confirmed that this virus was more genetically related to SIV from 
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the sooty mangabey (Cercocebus atys) than to HIV-1, which shows more genetic relatedness 
to SIV from the chimpanzee (Pan troglodytes troglodytes) (Figure 1).  This virus, which was 
originally known as lymphadenopathy-associated virus type 2, is presently known as human 




Figure 1:  Phylogenetic relationship of pol region of primate lentiviruses (McGrath et al., 






1.3 HIV-2 Structure  
 
Like HIV-1, HIV-2 is a retrovirus associated with AIDS.  The HIV-2 virion consists  of a 
complex genome surrounded by a cone-shaped capsid (Turner and Summers, 1999).  A lipid 
bilayer, derived from the host cell membrane functions as the envelope; surface glycoproteins 
(gp125) are anchored to the viral surface via the gp36 transmembrane protein.  This lipid 
bilayer also comprises of proteins, including major histocompatibility complex (MHC) 
antigens, actin and ubiquitin – all of which are host-cell derived.  The matrix protein (p17) is 
found on the inner surface of the virion.  This surrounds a conical capsid core (p24) particle 
comprised of approximately 2000 capsid proteins.  This centralized core further encapsidates 
two copies of the  viral RNA genome, which in association with the capsid, is known as 
ribonucleoprotein complex (Turner and Summers, 1999, Björling et al., 1994).  The three 
structural genes (gag, pol, and env) contain information needed to make structural proteins 
for new virus particles.   A diagrammatic representation of the structure of HIV is shown in 







Figure 2:  Diagrammatic representation of the HIV virion 




1.4 HIV-2 Genetics 
 
While both HIV-1 and HIV-2 belong to the Lentivirinae subfamily, there is only 
approximately 40% genetic similarity between these two viruses (Bock and Markovitz, 
2001).   HIV-2 consists of two identical copies of single-stranded RNA molecules.  The 9.2 
kb genome encodes nine open reading frames: gag, pol, vif, vpr, tat, rev, vpx, env and nef, 
which is flanked by the 5’ and 3’ long terminal repeats (Azevedo-Pereira, 2013).  Viral 
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enzymes protease (PRO), reverse transcriptase (RT) and integrase (INT) form part of the 
polymerase gene, as in HIV-1.  The three structural genes (gag, pol and env) are the same for 
all retroviruses (Fanales-Belasio et al., 2010) although the vpu gene of HIV-1 and SIV of 
chimpanzees is replaced by the vpx gene present in HIV-2 and SIV of sooty mangabeys.  The 
function of vpx is unclear but it may have functions associated with nuclear import (Reeves 






Figure 3:  Comparison of genetic organization between (A) HIV-1 and (B) HIV-2 









1.5 HIV-2 Epidemiology 
 
Further differences exist from a geographic perspective; worldwide, the predominant virus is 
HIV-1, accounting for approximately 95% of global HIV infections (Figure 4).  HIV-2, 
however, is concentrated mainly in West Africa (Zeh et al., 2005, Nielsen and Bryson, 2000, 




Figure 4:  Geographic distribution of HIV-1 subtypes and HIV-2 worldwide (Nielsen 




HIV-2 cases have, however, been reported in Europe, India and the United States, as well as 
areas with historical and socio-economic ties to West Africa.  For instance, in Portugal, HIV-
2 is responsible for 4.5% of the AIDS cases, and in France 1.8% of new infections are due to 
HIV-2 (Campbell-Yesufu and Gandhi, 2011).  The predominant genotype is subtype A and it 
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accounts for the majority of HIV-2 infections in Guinnea-Bissau and Europe.  Subtype B 
appears to have originated from the eastern parts of West Africa.  Sierra Leone has the 
greatest diversity of HIV-2 subtypes (A, B E and F) (Reeves and Doms, 2002).  Recently, an 
intersubtype recombinant involving subtypes A and B was described in Cameroon (Ntemgwa 




1.6 HIV and KwaZulu-Natal Province, South Africa 
 
KwaZulu-Natal (KZN) is the province with the highest HIV prevalence in South Africa (SA), 
which in turn is the country with the highest HIV prevalence in the world (UNAIDS, 2013).  
The appearance of HIV-2 in other geographic areas outside its origin has reflected 
associations with individuals of West African origin, hence the spread of HIV-2 worldwide 
may be attributed to the migration of these infected individuals (Quinn, 1994, Gao et al., 




It is not unlikely that HIV-2 may be present in SA, following high levels of population 
immigration to the country (Lehohla, 2011).  In addition, KZN hosts the two largest harbours 
in the country (Durban and Richards Bay), which contribute to the increase in the number of 
foreign individuals in the province (Young, 2012).  A dramatic increase in migration of 
individuals from African countries into South Africa raises concerns over the prevalence of 
HIV-2 infection in South Africa (Singh et al., 2013).  Moreover, it is virtually impossible to 
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know how many undocumented migrants reside in South Africa, or where they come from. It 





1.7 HIV-2 Pathogenesis 
 
Differences between HIV-1 and HIV-2 infections remain largely unexplained.  In contrast to 
the wealth of knowledge of HIV-1, there is still a paucity of data regarding crucial aspects of 
HIV-2. 
HIV-2 shares the same transmission routes as HIV-1, although the rates of sexual and 
perinatal transmission are significantly lower in HIV-2 infections.  In contrast to HIV-1, 
HIV-2 – infected individuals display decreased plasma and semen viral loads, thereby 
contributing to a slower immune deterioration and reduced transmission rates (Jerome, 2010).  
Substantial differences in disease development have also been observed in HIV-1 and HIV-2 
infections.  Both virus types lead to clinically indistinguishable AIDS, although the period 
between infection and the development of AIDS is substantially longer in HIV-2 – infected 




This difference in progression to AIDS in HIV-2 infections may be largely due to differences 
in viral loads.  This is true for other lentiviral infections; SIVsm-infected macaques showed 
correlating levels of plasma viremia and rates of AIDS-associated disease.  Similarly, higher 
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viral loads are associated with a more rapid disease progression in cats infected with feline 




To further support this, Popper et al showed that differences in HIV-1 and -2 viral loads are a 
key attribute to the differences in pathogenicity between these two viruses, showing that  the 
median viral load was 30 times lower in HIV-2–infected individuals (Popper et al., 1999).  
While similar proviral loads exist in both types of infection, HIV-2 plasma viral loads are 
significantly lower than HIV-1 (Singh et al., 2013).  This difference may account for the 
attenuated disease seen in HIV-2 infections.  Additional research into the biological 
differences between these two virus types may provide insight into the pathogenic 




1.8 Dual Infection  
 
Many studies have recognized co-infection with HIV types 1 and 2, which are common in 
areas with a high HIV-2 prevalence, such as West Africa (George et al., 1992, Campbell-
Yesufu and Gandhi, 2011, Landman et al., 2009).  It has been documented that infection with 
HIV-2 confers some degree of protection against subsequent infection with the more virulent 
HIV type 1.  Travers et al demonstrated this protective effect to be approximately 70% 
against HIV-1 superinfection in HIV-2 infected high-risk female sex workers in Dakar, 
Senegal.  The mechanism by which HIV-2 alters the natural course of HIV-1 infection 
10 
 
remains unclear.  It has been proposed that this protection may be attributed to the robust 




In vitro studies show that HIV-1 replication can be inhibited by HIV-2 interference through 
an unidentified molecular pathway.  Other studies revealed that the HIV-2 tat activation-
response region (TAR) can act as an inhibitor of HIV-1 replication by suppressing replication 
in cells co-infected by both virus types (Browning et al., 1999, Kokkotou et al., 2000).  Other 
mechanisms such as receptor-mediated viral interference were proposed by Martin and 
Nayak, who demonstrated that HIV-1 and -2 both compete for the same target cell receptor 
(CD4) and that infection with one virus type may down-regulate the cell receptor, thereby 




Recombination events between dually infected cells may occur, resulting in progeny virions 
which are mosaics of the two parent strains.  This is associated with the increased diversity 
and variation seen in HIV.  These recombination events between HIV-1 and HIV-2, however, 








1.9 Laboratory Diagnosis 
 
The genetic and antigenic similarity between HIV types 1 and 2 presents an HIV-2 diagnostic 
dilemma; serological assays that unambiguously differentiate between HIV types 1 and 2 are 
lacking.  In addition, molecular laboratory methods which are used to monitor treatment 
(viral load quantification) and diagnose HIV infection (PCR) or sequence the virus (to 




An HIV-2 specific Western blot is done for serological confirmation of infection, where 
seropositivity requires antibody reactivity to env + gag + pol antigens, or to 2 env antigens 
(Kanki and Meloni, 2004).  However, HIV-2 type-specific Western blots also display a high 
degree of non-specificity (Qiu et al., 2009).  The high degree of cross-reactivity between 




Consequently, HIV-2 – infected individuals are at risk of misdiagnosis and treatment failure 
since HIV diagnostic testing and viral load quantification are specific for HIV-1.  Resistance 







1.10 HIV-2 Treatment 
 
In vitro analyses of the efficacy of available antiretroviral therapy (ART) against HIV-2 has 
not been thoroughly explored.  In addition, all approved antiretroviral drugs were designed to 
specifically target HIV-1 (Witvrouw et al., 2004, Kanki and Meloni, 2004).  Since HIV-1 and 
-2 RT and Pro are structurally and functionally similar, it is possible that some antiretroviral 
agents with broad activity may be effective against HIV-2.  However, due to the distant 
genetic makeup between these two viruses (approximately only 60% similarity at nucleotide 
level in the PRO and RT genes), equal activity is not guaranteed against these two virus types 
(Witvrouw et al., 2004).  In fact, it has been established that certain antiretrovirals work less 




HIV-2 is naturally resistant to all drugs in the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) group that are presently available:  in some instances, there is greater than a 200-
fold decrease in susceptibility of HIV-2 to nevirapine, delavirdine and efavirenz (Witvrouw 
et al., 2004, Rodes et al., 2005).  The differences between HIV-1 and -2 at the genomic level 
of RT are featured in Figure 5, with emphasis on regions associated with HIV-1 
NRTI/NNRTI drug resistance.  HIV-2 also displays resistance to the fusion inhibitor T-20 






Zidovudine and other nucleoside reverse transcriptase inhibitors (NRTI) have demonstrated 
efficacy against HIV-2 with the development of resistance and their patterns being similar in 
HIV-1 and HIV-2 infections (Mullins et al., 2004). Treatment regimens with nucleoside 







Figure 5:  Nucleotide differences between HIV-1 and HIV-2 in the reverse transcriptase 
region of the genomes (Ntemgwa et al., 2009). Highlighted areas are those with 






Weber et al showed that differences in the protease genetic sequences reveal that HIV-2 may 
be constitutively resistant to  protease inhibitors (PIs); sites of the genome associated with 
protease resistance in HIV-1 are similar to wild-type protease sequences of HIV-2 (Weber et 
al., 1997).  This was confirmed by the results of a study by Witvrouw et al, who 
demonstrated a reduced potency of PI’s, amprenavir in particular, against HIV-2 in vitro 
(Witvrouw et al., 2004).  Hence, PI-containing regimens that are active against HIV-1, may 
demonstrate reduced potency against HIV-2.  Other studies have shown, however, that 
treatment with dual PI or NRTI-PI combination regimens results in clinical improvement 




The genetic differences between HIV-1 and -2 protease region are highlighted in Figure 6, 






Figure 6:  Nucleotide differences between HIV-1 and HIV-2 in the protease region of the 
genomes (Ntemgwa et al., 2009).  Highlighted areas are those with polymorphisms at 
positions involved in HIV-1 protease resistance.  Dots are indicative of sequence similarity. 
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1.11 Aims and Objectives 
 
 To determine the prevalence of HIV-2 infection in KZN 
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CHAPTER 3:  SUMMARY AND CONCLUSIONS 
 
 Vast differences exist between HIV-1 and HIV-2.  These include differences in rates of 
disease transmission, laboratory diagnosis as well as treatment strategies.  HIV-2 is 
generally less pathogenic than HIV-1; disease progression occurs at a slower rate in HIV-
2 and the clinical latency period is longer.   The HIV-2 attenuated phenotype may be 
associated with the limited geographic distribution demonstrated by HIV-2 compared to 




 Cross-reacting antibodies between HIV-1 and -2 are not uncommon and misclassification 
of these infections is quite likely.  Using serology alone may, therefore, grossly 




 Serological diagnosis of HIV-2 infection should be interpreted with caution as there is a 
high level of false-positivity which reduces the specificity of these assays.  Western blots, 
which are capable of HIV type-specific differentiation, can be useful in HIV-2 diagnosis.  
Results for these assays should be interpreted based on the manufacturer’s criteria for 
interpretation, and also according to WHO guidelines, to decrease the number of 




 Short peptide-based immunoassays such as the Pepti-LAV assay used in this study proved 
to be a more reliable indicator of HIV-2 infection than the Western blot.  The increased 
specificity of this assay was comparable to that of the Western blot (seroprevalence of 
1.6% versus 10.7%).  As a result, a more specific immunoassay will provide more 




 PCR for molecular detection of HIV-2 provides a much more reliable tool for 
confirmation of infection.  The primers used should be broad enough to cover the genetic 
diversity of HIV-2 subtypes, but remaining specific to the HIV-2 genome.  Of note, HIV-
1 and -2 share an approximately 60% homology in conserved genes (gag and pol) and 
between 35% - 45% in the env genes (Jerome, 2010).  Primers used for PCR detection 




 PCR, however, cannot be used as the ultimate confirmatory assay for HIV-2 diagnosis 
due to low plasma viral loads, which are common in HIV-2 infections.   The lower HIV-2 
RNA levels found in the blood plasma compartment may be associated with reduced 
sensitivity of molecular assays such as PCR, for example.   
 
 
 The sample type used is also relevant for correct HIV-2 diagnosis.  Like other 
retroviruses, HIV-2 induces a lifelong infection, by integration of the viral genome into 
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the host cell’s DNA.  Consequently, the ideal sample type for molecular confirmation of 
HIV-2 infection is a whole blood sample which has peripheral blood mononuclear cells 
(PBMCs) to detect this HIV-2 proviral DNA.  A limitation of this study is that the only 
available sample types were serum and plasma samples.  These were subsequently used in 
this study, but were, however, deemed suitable based on sensitivity experiments and HIV-




 HIV-2 is largely confined to West Africa and the spread is mainly attributed to population 
migration of infected individuals.  This study aimed to determine the prevalence of HIV-2 
in KZN, a region where HIV-1 subtype C is highly prevalent.  The results show that HIV-




 The differences highlighted in this study have important diagnostic, clinical and treatment 
implications.  Reliable methods for differentiating between HIV-1 and -2 infections need 
to be established and this is an avenue for future research.  Continued population 















AYINDE, D., MAUDET, C., TRANSY, C. & MARGOTTIN-GOGUET, F. 2010. Limelight 
on two HIV/SIV accessory proteins in macrophage infection: Is Vpx overshadowing 
Vpr? Retrovirology, 7. 
 
AZEVEDO-PEREIRA, J. M. 2013. HIV-2 Interaction with Target Cell Receptors, or Why 




BJÖRLING, E., CHIODI, F., UTTER, G. & NORRBY, E. 1994. Two neutralizing domains 
in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol, 152, 
1952-1959. 
 
BLACKARD, J. T., COHEN, D. E. & MAYER, K. H. 2002. Human immunodeficiency virus 
superinfection and recombination: current state of knowledge and potential clinical 
consequences. Clin Infect Dis, 34, 1108-1114. 
 
BOCK, P. J. & MARKOVITZ, D. M. 2001. Infection with HIV-2. AIDS, 15, S35-S45. 
 
BROWNING, C. M., CAGNON, L., GOOD, P. D., ROSSI, J., ENGELKE, D. R. & 
MARKOVITZ, D. M. 1999. Potent inhibition of human immunodeficiency virus type 
1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response 




CAMPBELL-YESUFU, O. T. & GANDHI, R. T. 2011. Update on human immunodeficiency 
virus (HIV)-2 infection. Clin Infect Dis, 52, 780-787. 
 
COX, S. W., APERIA, K., ALBERT, J. & WAHREN, B. 1994. Comparison of the 
sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and 
drug combinations. AIDS Res Hum Retroviruses, 10, 1725-1729. 
 
DAMOND, F., WOROBEY, M., CAMPA, P., FARFARA, I., COLIN, G., MATHERON, S., 
BRUN-VEZINET, F., ROBERTSON, D. L. & SIMON, F. 2004. Identification of a 
highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. 
AIDS Res Hum Retroviruses, 20, 666-72. 
 
FANALES-BELASIO, E., RAIMONDO, M., SULIGOI, B. & BUTTÒ, S. 2010. HIV 
virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super 
Sanità, 46, 5-14. 
 
GAO, F., YUE, L., ROBERTSON, D. L., HILL, S. C., HUI, H., BIGGAR, R. J., 
NEEQUAYE, A. E., WHELAN, T. M., HO, D. D. & SHAW, G. M. 1994. Genetic 
diversity of human immunodeficiency virus type 2: evidence for distinct sequence 
subtypes with differences in virus biology. J Virol, 68, 7433-7447. 
GEORGE, J., OU, C., PAREKH, B., BROWN, V., DE COCK, K., BRATTEGAARD, K. & 
BOATENG, E. 1992. Prevalence of HIV-1 and HIV-2 mixed infections in Cote 




JEROME, K. R. 2010. Lennette's laboratory diagnosis of viral infections 4th ed., Informa 
Healthcare USA, Inc. 
 
KANKI, P. J. & MELONI, S. T. 2004. Biology and Variation in HIV-2 and HIV-1. Available 
at: http://ftguonline.org/ftgu-232/index.php/ftgu/article/view/1969/3934 
 
KOKKOTOU, E. G., SANKALÉ, J.-L., MANI, I., GUÈYE-NDIAYE, A., SCHWARTZ, D., 
ESSEX, M. E., MBOUP, S. & KANKI, P. J. 2000. In vitro correlates of HIV-2-
mediated HIV-1 protection. Proc Natl Acad Sci, 97, 6797-6802. 
 
LANDMAN, R., DAMOND, F., GERBE, J., BRUN-VEZINET, F., YENI, P. & 
MATHERON, S. 2009. Immunovirological and therapeutic follow-up of HIV-1/HIV-
2-dually seropositive patients. AIDS, 23, 426-428. 
 
LEHOHLA, P. 2011. Mid-year Population Estimates, 2011.  Statistics South Africa. 
 
LEMEY, P., PYBUS, O. G., WANG, B., SAKSENA, N. K., SALEMI, M. & VANDAMME, 
A.-M. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad 
Sci, 100, 6588-6592. 
MARTIN, R. A. & NAYAK, D. P. 1996. Receptor interference mediated by the envelope 
glycoproteins of various HIV-1 and HIV-2 isolates. Virus research, 45, 135-145. 
 
MCGRATH, K. M., HOFFMAN, N. G., RESCH, W., NELSON, J. A. & SWANSTROM, R. 





MULLINS, C., EISEN, G., POPPER, S., SARR, A. D., SANKALÉ, J.-L., BERGER, J. J., 
WRIGHT, S. B., CHANG, H. R., COSTE, G. & COOLEY, T. P. 2004. Highly active 
antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis, 38, 
1771-1779. 
 
NIELSEN, K. & BRYSON, Y. J. 2000. Diagnosis of HIV infection in children. Pediatr Clin 
North Am, 47, 39-63. 
 
NTEMGWA, M. L., TONI, T. D. A., BRENNER, B. G., CAMACHO, R. J. & WAINBERG, 
M. A. 2009. Antiretroviral drug resistance in human immunodeficiency virus type 2. 
Antimicrob Agents Ch, 53, 3611-3619. 
 
POPPER, S. J., SARR, A. D., TRAVERS, K. U., GUÈYE-NDIAYE, A., MBOUP, S., 
ESSEX, M. E. & KANKI, P. J. 1999. Lower Human Immunodeficiency Virus (HIV) 
Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV-1 and HIV-2. J 
Infect Dis, 180, 1116-1121. 
QIU, M., LIU, X., JIANG, Y., NKENGASONG, J. N., XING, W., PEI, L. & PAREKH, B. S. 
2009. Current HIV-2 diagnostic strategy overestimates HIV-2 prevalence in China. J 
Med Virol, 81, 790-797. 
 
QUINN, T. C. 1994. Population migration and the spread of types 1 and 2 human 




REEVES, J. D. & DOMS, R. W. 2002. Human immunodeficiency virus type 2. J Gen Virol, 
83, 1253-1265. 
 
RODES, B., TORO, C., JIMENEZ, V. & SORIANO, V. 2005. Viral response to 
antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect 
Dis, 41, e19-21. 
 
SINGH, L., PARBOOSING, R., MANASA, J., MOODLEY, P. & DE OLIVEIRA, T. 2013. 
High level of HIV-2 false positivity in KwaZulu-Natal province: a region of South 
Africa with a very high HIV-1 subtype C prevalence. J Med Virol, 85, 2065 - 2071. 
 
SMITH, R. A., GOTTLIEB, G. S., ANDERSON, D. J., PYRAK, C. L. & PRESTON, B. D. 
2008. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities 
to zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Ch, 
52, 329-332. 
 
SORIANO, V., GOMES, P., HENEINE, W., HOLGUIN, A., DORUANA, M., ANTUNES, 
R., MANSINHO, K., SWITZER, W. M., ARAUJO, C. & SHANMUGAM, V. 2000. 
Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, 
circulating subtypes, virus isolation, and plasma viral load. J Med Virol, 61, 111-116. 
 
TRAVERS, K., MBOUP, S., MARLINK, R., GUEYE-NIDAYE, A., SIBY, T., THIOR, I., 
TRAORE, I., DIENG-SARR, A., SANKALE, J.-L. & MULLINS, C. 1995. Natural 




TURNER, B. G. & SUMMERS, M. F. 1999. Structural biology of HIV. J Mol Biol, 285, 1-
32. 
 
UNAIDS 2013. UNAIDS report on the Global AIDS Epidemic 2013. 
 
WEBER, J., MAJER, P., LITERA, J., URBAN, J., SOUČEK, M., VONDRÁŠEK, J., 
KONVALINKA, J., NOVEK, P., SEDLÁČEK, J. & ŠTROP, P. 1997. Potency 
comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: 
design of equipotent lead compounds. Arch Biochem Biophys, 341, 62-69. 
 
WITVROUW, M., PANNECOUQUE, C., SWITZER, W. M., FOLKS, T. M., DE CLERCQ, 
E. & HENEINE, W. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-
HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir 
Ther, 9, 57-66. 
YOUNG, J. 2012. Regional Overview of KwaZulu-Natal. KwaZulu-Natal Business 2012/13, 
10 - 15. 
 
ZEH, C., PIENIAZEK, D., AGWALE, S. M., ROBBINS, K. E., ODAMA, L., SANI-
GWARZO, N., GBOUN, M. S., INYANG, U. S., FOLKS, T. M., WAMBEBE, C. & 
KALISH, M. L. 2005. Nigerian HIV type 2 subtype A and B from heterotypic HIV 
type 1 and HIV type 2 or monotypic HIV type 2 infections. AIDS Res Hum 
Retroviruses, 21, 17-27. 
 
 
 
 
